BDC Capital's $150M Life Sciences Fund: Canada's Medtech Layer Gets Capital
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
2026 venture capital activity reflects a market balancing AI infrastructure bets, selective growth equity, and renewed interest in capital-efficient startups. Our coverage tracks the rounds, fund launches, and strategic shifts that matter for founders and investors.
Read the latest 2026 VC news and funding roundups below.
BDC Capital's life sciences venture fund bolsters Canadian therapeutics and medtech — an underrated pipeline for U.S. and EU follow-on rounds.
Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.
Blackstone's opportunistic private credit fund is not VC, but its scale directly changes how venture-backed companies refinance, recapitalize, and exit.
Mega buyout funds like KKR's 2026 vehicle aren't traditional VC, but they materially influence late-stage startup exits and crossover rounds.
Alcatraz's April 2026 round reflects growing demand for privacy-aware biometric access systems in critical facilities.
From NYC seed activity to U.S. AI infrastructure rounds, April 2026 deal flow shows where capital is concentrating and what founders should do next.